Welcome to our dedicated page for Alphatec Hldgs news (Ticker: ATEC), a resource for investors and traders seeking the latest updates and insights on Alphatec Hldgs stock.
Alphatec Holdings Inc (ATEC) delivers innovative spinal surgery solutions through advanced medical technologies designed to improve surgical outcomes. This news hub provides investors and healthcare professionals with essential updates on the company's latest developments in spinal fusion systems, regulatory milestones, and strategic partnerships.
Access authoritative information about ATEC's product innovations, including solutions for Posterior Cervical Fusion and Lateral Interbody Fusion procedures. Our curated collection features earnings announcements, clinical trial updates, and executive leadership changes - all critical for understanding the company's market position.
Key updates include:
- New product approvals and surgical device launches
- Financial performance reports and investor communications
- Collaborations with spine surgeons and research institutions
- Industry recognition and patent developments
Bookmark this page for ongoing access to verified information about Alphatec's contributions to spinal care technology. Check regularly for objective updates that matter to both clinical practitioners and investment decision-makers.
Alphatec Holdings (ATEC) reported strong Q3 2024 results with total revenue reaching $151 million, driven by 30% surgical revenue growth and 27% total revenue growth. The company achieved a GAAP gross margin of 68% and recorded a GAAP net loss of $40 million. Key operational highlights include 20% procedural volume growth, 19% growth in new surgeon adoption, and over 200 surgeon training engagements. ATEC secured a $50 million expansion of its existing term loan facility, bringing total capacity to $200 million. The company raised its full-year 2024 guidance, now expecting total revenue of $605 million and adjusted EBITDA of $27 million.
Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative spine surgery solutions, has announced it will report its third quarter 2024 financial results on October 30, 2024, after market close. The company will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day.
To access the webcast, investors can visit the Investor Relations Section of ATEC's Corporate Website. For those wishing to dial in, registration is required via a provided link. A replay of the webcast will be available for twelve months.
Additionally, ATEC has granted 49,969 restricted stock units (RSUs) to 12 new non-executive employees as an employment inducement. These RSUs will vest in equal annual installments over four years, subject to continued employment, and will fully vest upon a change of control of ATEC.
Alphatec Holdings (Nasdaq: ATEC) will showcase its informatics-integrated spine procedures at the North American Spine Society (NASS) 29th Annual Meeting from September 25-27, 2024, in Chicago. The company will highlight its approach-specific technologies coupled with proprietary informatics like EOS Insight and SafeOp to improve spine surgery outcomes. Key presentations include a demonstration of ATEC's Prone TransPsoas (PTP) Approach and discussions on lateral surgery evolution and EOS Insight's impact on deformity surgery durability.
Additionally, ATEC granted 38,374 restricted stock units (RSUs) to 14 new employees as employment inducements, vesting over four years or fully upon a change of control.
Alphatec Holdings (NASDAQ:ATEC) reported strong Q2 2024 financial results, with total revenue growing 25% to $146 million. Surgical revenue increased by 27%, driving overall growth. The company has raised its full-year guidance, now expecting total revenue to grow 25% to $602 million and non-GAAP adjusted EBITDA of approximately $25.5 million.
Key highlights include the launch of EOS Insight™, expansion in major markets, 20% growth in new surgeon adoption, and the appointment of Keith Valentine to the Board of Directors. ATEC achieved profitability milestones and continues to focus on self-funded growth. The company's strategic initiatives and spine-focused approach are yielding positive results, positioning ATEC for continued success in the spine surgery market.
Alphatec Holdings (ATEC), a spine surgery solutions provider, announced its participation in four upcoming investor conferences:
- RBC West Coast Medical Device Bus Tour on August 14, 2024
- Piper Sandler MedTech and Diagnostics California Bus Tour on August 21, 2024
- Morgan Stanley Global Healthcare Conference on September 4, 2024
- Wells Fargo Healthcare Conference on September 5, 2024
Live webcasts, if available, will be accessible on ATEC's Investor Relations website. Additionally, ATEC granted 44,772 restricted stock units (RSUs) to 22 new non-executive employees as employment inducement. These RSUs will vest over four years and fully upon a change of control.
ATEC (Nasdaq: ATEC) has launched EOS Insight, an innovative end-to-end spine surgery platform powered by EOSedge scans and AI. The first EOS Insight-informed surgeries were successfully performed at OrthoIndy Hospital. This groundbreaking platform leverages AI to provide important information throughout multiple stages of spine care, including:
- AI-driven alignment calculation
- 3D-surgical planning simulations
- Patient-specific rods
- Intra-operative reconciliation
- Post-operative analytics
EOS Insight aims to modernize spine surgery by replacing archaic clinical practices and improving patient outcomes. The platform's ability to automate processes and integrate alignment data into surgical plans positions ATEC as a potential standard-bearer in spine care.
Alphatec Holdings (Nasdaq: ATEC) announced it will report its Q2 2024 financial results on July 31, 2024, after the market close. A live webcast will be hosted at 1:30 p.m. PT / 4:30 p.m. ET, accessible through the Investor Relations section of the company's website. Participants can dial into the webcast after registering online, and a replay will be available for twelve months.
In related news, ATEC's independent Compensation Committee approved inducement grants for 30 new employees, totaling 47,112 restricted stock units (RSUs). These RSUs will vest annually over four years, contingent on continuous employment, and will fully vest upon a change of control of the company.
Alphatec Holdings, Inc. (Nasdaq: ATEC) reported a 27% growth in total revenue to $138 million, with 30% increase in surgical revenue. Adjusted EBITDA margin expanded by 450 basis points. Full-year revenue and adjusted EBITDA guidance raised to $601 million and $23 million respectively. The company experienced growth in surgical revenue, surgeon adoption, and U.S. footprint expansion. Ending cash balance was $144 million. Non-GAAP gross margin was 71%. The CEO expressed confidence in the company's future growth potential.
Alphatec Holdings, Inc. (Nasdaq: ATEC) will be participating in several investor conferences in May and June 2024. The company also granted 14,024 restricted stock units to new employees as an inducement to accepting employment, which will vest in equal annual installments on each of the first four anniversaries of the grant date, contingent on the recipient's continuous employment with ATEC.
FAQ
What is the current stock price of Alphatec Hldgs (ATEC)?
What is the market cap of Alphatec Hldgs (ATEC)?
